Radiology Partners' Cognita Chest X-ray AI tool earns FDA Breakthrough Device status for multiple clinical uses.
Key Details
- 1Radiology Partners' Cognita business received FDA Breakthrough Device designation for its Chest X-ray AI tool.
- 2The tool uses a generative vision-language model to assist radiologists in X-ray interpretation.
- 3This is among the first vision-language AI solutions in radiology to receive this designation.
- 4Breakthrough status expedites regulatory review for devices addressing critical needs.
- 5Cognita CXR integrates into radiology workflows to generate comprehensive preliminary reports for physician review.
Why It Matters
FDA Breakthrough Device designation is a major step for AI-driven radiology tools, signaling both clinical promise and regulatory progress. This can accelerate the path toward broader clinical deployment of advanced AI models in everyday radiology practice.
Source
Radiology Business
Related News
•HealthExec
Mayo Clinic Sued Over Alleged AI Improprieties and Whistleblower Retaliation
A former Mayo Clinic research director sues the institution, alleging retaliation after raising concerns about improper AI use affecting patient safety and data integrity.
•Radiology Business
Generative AI Set to Transform Chest X-ray Reporting and Quality
Generative AI models can now produce full radiology reports from chest X-rays, promising increased diagnostic accuracy and efficiency.
•Radiology Business
Radiology Dominates FDA AI Algorithm Clearances in 2026
Radiology accounted for 68 new FDA-cleared AI algorithms in early 2026, making up more than three-quarters of all AI clinical clearances.